MarketPR
WORLDNeil Bush backs Texas Democrat Talarico in Senate raceOct 24PRODUCTKate Gosselin says her kids know who she truly is as son Collin levels abuse allegationsOct 24WORLDOmar's deleted tweet could give clue on alleged brother marriageOct 24DEALSFive dividend stocks yield over 5% despite current headwindsOct 24MARKETSFour historical indicators signal potential stock market crashOct 24WORLDTrump Advisers See Middle East Opportunities Beyond NetanyahuOct 24CRYPTOAI-generated Jon Bon Jovi videos trick Louisiana woman into $10K lossOct 24WORLDLawmakers urge AI leaders to stop warning of existential doomOct 24REGULATORYIlhan Omar admits uncertainty on family ties amid immigration fraud probeOct 24REGULATORYNYC carriage ban faces expected legal challenges over constitutionalityOct 24WORLDNeil Bush backs Texas Democrat Talarico in Senate raceOct 24PRODUCTKate Gosselin says her kids know who she truly is as son Collin levels abuse allegationsOct 24WORLDOmar's deleted tweet could give clue on alleged brother marriageOct 24DEALSFive dividend stocks yield over 5% despite current headwindsOct 24MARKETSFour historical indicators signal potential stock market crashOct 24WORLDTrump Advisers See Middle East Opportunities Beyond NetanyahuOct 24CRYPTOAI-generated Jon Bon Jovi videos trick Louisiana woman into $10K lossOct 24WORLDLawmakers urge AI leaders to stop warning of existential doomOct 24REGULATORYIlhan Omar admits uncertainty on family ties amid immigration fraud probeOct 24REGULATORYNYC carriage ban faces expected legal challenges over constitutionalityOct 24
NewsMacro · NVO

Novo's Wegovy Pill Still Leads the GLP-1 Pill Market as Lilly's Foundayo Launches

Novo Nordisk's Wegovy pill remains a top choice among Americans for weight loss even after the launch of Foundayo, Eli Lilly's GLP-1 pill, according to MarketWatch.

By Talia GreenwoodMacro DeskJune 9, 20262 min readNVO ·LLY
Share

Key takeaways

  • Novo Nordisk's Wegovy pill remains a top choice among Americans for weight loss even after the launch of Eli Lilly's Foundayo GLP-1 pill, according to MarketWatch.
  • Novo Nordisk (NVO) and Eli Lilly (LLY) are now competing directly in the oral GLP-1 weight-loss market.
  • The entry of Foundayo has not, at least so far, displaced Novo's Wegovy pill from the top of consumers' preferences.
  • The specific market-share split, sales figures for either product, and Foundayo's launch date were not stated in the source.
  • It was not specified what underlying data was used to characterize the Wegovy pill as a top choice.

Novo Nordisk's Wegovy pill remains a top choice among Americans for weight loss even after the launch of Foundayo, Eli Lilly's GLP-1 pill, according to MarketWatch.

The two drugmakers are now competing directly in the oral GLP-1 weight-loss market. Novo Nordisk (NVO) markets the Wegovy pill, while Eli Lilly (LLY) has entered the same segment with the recent launch of its own GLP-1 pill, Foundayo.

Per the source, Wegovy's pill has held its standing as a leading option among American consumers despite the arrival of a direct competitor. In other words, the entry of Foundayo has not, at least so far, displaced the Novo product from the top of consumers' preferences as described by MarketWatch.

The report frames the situation as head-to-head oral GLP-1 competition between the two companies. The specific market-share split between the Wegovy pill and Foundayo was not stated in the materials available for this report. Sales figures for either product were likewise not provided. The launch date for Foundayo was not specified.

It was not specified what underlying data — such as prescription volumes, surveys, or other metrics — was used to characterize the Wegovy pill as a "top choice". Any pricing, dosing, or availability differences between the two pills were also not detailed in the source.

What it means for investors: The oral GLP-1 category has become a two-name contest between Novo Nordisk and Eli Lilly, and the early read in the source is that Novo's Wegovy pill has retained consumer preference even after Lilly's Foundayo reached the market. That is a snapshot of an evolving competitive dynamic rather than a settled outcome, and it is not investment advice or a buy or sell signal. Investors following the rivalry should confirm the specific market-share and sales figures, the timing of Foundayo's launch, and how each company frames the pill opportunity in its own disclosures before drawing conclusions, and should weigh this single report alongside broader coverage and their own assessment of both companies.

Source: MarketWatch

About this story

Filed by the macro desk of MarketPR on June 9, 2026. Source: editorial.local. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

Four historical indicators signal potential stock market crash

Four historically reliable metrics are currently signaling that a stock market crash or bear market may be imminent, according to a recent analysis. These indicators include elevated valuations, record margin debt, the historical pattern…

Miles Broadbent2 min read
02Macro

US stocks slip pre-bell as AI spending concerns persist

US equity benchmarks traded lower in premarket activity Friday, with the S&P 500 down 0.1% and the Dow Jones Industrial Average declining 0.5%, as investor caution over artificial intelligence expenditures continued to weigh on sentiment…

Miles Broadbent2 min read
03Macro · AAPL

Apple passes Nvidia in market cap as Anthropic IPO nears

Apple (AAPL) has overtaken Nvidia (NVDA) as the world's most valuable public company, a shift driven by Nvidia's recent stock decline and strong demand for Apple's new foldable smartphone. Yahoo Finance Executive Editor Brian Sozzi…

Grant Halloran2 min read

Frequently asked

Which GLP-1 weight-loss pill is currently leading the market?

Novo Nordisk's Wegovy pill remains a leading option among American consumers, even after the launch of Eli Lilly's competing Foundayo pill, according to MarketWatch.

What is Foundayo?

Foundayo is Eli Lilly's GLP-1 weight-loss pill, recently launched to compete directly with Novo Nordisk's Wegovy pill in the oral GLP-1 market.

What is the market-share split between Wegovy's pill and Foundayo?

The specific market-share split between the two products was not stated in the materials available for this report, nor were sales figures for either product.

When did Foundayo launch?

The launch date for Foundayo was not specified in the source.

Is this report investment advice?

No, the report describes a snapshot of an evolving competitive dynamic and is explicitly not investment advice or a buy or sell signal.